Anti-MYC Polyclonal Antibody

Catalog No.

PHB90801

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human MYC (Glu351-Ser437).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Proto-oncogene c-Myc,BHLHE39,MYC,Myc proto-oncogene protein,bHLHe39,Transcription factor p64,Class E basic helix-loop-helix protein 39

Purification

Purified by antigen affinity column.

Accession

P01106

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Nanobody-based fluorescent immunoassay for SARS-CoV-2 spike detection via site-specific microbial transglutaminase labeling., PMID:40483875

Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma., PMID:40440582

B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies., PMID:40435909

Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor., PMID:40433120

B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements., PMID:40402557

Deciphering the history of ERK activity from fixed-cell immunofluorescence measurements., PMID:40399273

Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice., PMID:40359088

Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN., PMID:40353332

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer., PMID:40346041

The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells., PMID:40301616

Astrocyte Elevated Gene-1/Metadherin (AEG-1/MTDH): A Promising Molecular Marker and Therapeutic Target for Hepatocellular Carcinoma., PMID:40282551

ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27., PMID:40281007

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse., PMID:40241199

Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma., PMID:40238894

Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report., PMID:40230856

ID3 enhances PD-L1 expression by restructuring MYC to promote colorectal cancer immune evasion., PMID:40208940

Ultrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 for the treatment of prostate cancer: an experimental study., PMID:40196732

Multimerized epitope tags for high-sensitivity protein detection., PMID:40191928

Establishment of a novel human basophil cell line for functional analysis and in vitro allergy testing., PMID:40187962

Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway., PMID:40175588

Current and future therapies for small cell lung carcinoma., PMID:40170056

Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2., PMID:40145086

Diffuse large B-cell lymphoma with partial low Ki67 proliferation index., PMID:40138154

Blood-brain barrier crossing biopolymer targeting c-Myc and anti-PD-1 activate primary brain lymphoma immunity: Artificial intelligence analysis., PMID:40088978

Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis., PMID:40010102

Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy., PMID:40009747

A dual-mode immunosensor for detection of oncoprotein c-Myc via indirect competition using trimetallic nanocomposite as an excellent label., PMID:39984205

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma., PMID:39951620

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence., PMID:39914385

PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny., PMID:39904797

Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets., PMID:39855192

Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer., PMID:39850893

Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma., PMID:39824386

Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer., PMID:39806366

Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa., PMID:39787450

Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors., PMID:39755583

Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study., PMID:39748728

[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma]., PMID:39743255

Antisense oligonucleotides-based approaches for the treatment of multiple myeloma., PMID:39732226

AptaFluorescence: An aptamer-based fluorescent imaging protocol for biomolecule visualization., PMID:39729513

Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442

Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells., PMID:39704178

ITGA3 promotes pancreatic cancer progression through HIF1α- and c-Myc-driven glycolysis in a collagen I-dependent autocrine manner., PMID:39690180

The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer., PMID:39679910

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma., PMID:39672382

Nanotechnology-Enabled Targeted Protein Degradation for Cancer Therapeutics., PMID:39663650

Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression., PMID:39639312

Prognostic Significance of C-MYC and EGFR Overexpression in Gastrointestinal Stromal Tumors: An Immunohistochemical Study., PMID:39636317

[The effect of c-Myc on regulating the immune-related ligands in Y subtype small cell lung cancer through histone deacetylase 1]., PMID:39622733

DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells., PMID:39616183

Document Download

Anti-MYC Polyclonal Antibody.pdf